Table 1.
Summary of clinical data of patients with chronic myeloid leukemia (CML) that participated in the study.
| New CML Diagnosis | CML on TKI | CML off TKI | CML Relapsed | ||
|---|---|---|---|---|---|
| Patients (n) | 6 | 45 | 27 | 15 | |
| Male/female (n) | 3/3 | 22/23 | 18/9 | 7/8 | |
| Median age (years) | 54.5y (IQR 44.7 to 64) | 49.0y (IQR 37.5 to 59) | 48.5y (IQR 39.7 to 65) | 38.0y (IQR 27 to 57) | |
| Sokal Risk Score (L/I/H/UD) * (n) | 3/2/1/0 | 34/6/5/0 | 17/7/0/3 | 13/2/0/0 | |
| Response at sampling ** (n) | CCyR | N/A | 4 | 0 | 10 |
| MMR | N/A | 8 | 0 | 0 | |
| DMR | N/A | 33 | 27 | 5 | |
| UD | N/A | 0 | 0 | 0 | |
* Sokal Risk, L = low/I = intermediate/H = high/UD = undetermined. ** Response at sampling: CCyR = complete cytogenetic response; MMR = major molecular response; DMR = deep molecular response, IQR = interquartile range; N/A = not applicable; y = years.